![]() Magnus was CEO of the combined transplantation and fertility company Vitrolife from January 2003 to October 2011. Steen, which resulted in the product STEEN Solution™. Perfadex was acquired and a successful collaboration was started with Prof. Peter Svalander, Vitrolife's visionary founder. The outgoing CEO Magnus Nilsson started XVIVO in 1998 with a focus on transplant products, on the advice and with the help of Dr. He holds an MBA from INSEAD and a BA (Hons) in Business and Commerce from the Stockholm School of Economics and is a Board member of Nolato AB, GHP AB and Terveystalo Oy. Dag has a background in biotechnology as CEO of Diaverum AB from 2008 up until 2018 and before that worked for 15 years in leading roles in Mölnlycke Health Care. Dag Andersson takes up his new position on June 1, 2020. XVIVO Perfusion AB's ("XVIVO") Board of Directors has decided to appoint Dag Andersson, 58, as President and CEO of XVIVO. At the same time Magnus Nilsson will remain as Senior Advisor to primarily work with R&D. Magnus Nilsson will hand over the baton to Dag Andersson as CEO of XVIVO Perfusion on June 1, 2020. Board and Senior Management share holdings.XVIVO LS™* & XVIVO Disposable Lung Set™. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |